Banzel

Banzel is a brand name of rufinamide, approved by the FDA in the following formulation(s):

BANZEL (rufinamide - suspension; oral)

• 
  Manufacturer: EISAI INC
  
  Approval date: March 3, 2011
  
  Strength(s): 40MG/ML ^[RLD]

BANZEL (rufinamide - tablet; oral)

• 
  Manufacturer: EISAI INC
  
  Approval date: November 14, 2008
  
  Strength(s): 200MG, 400MG ^[RLD]

Has a generic version of Banzel been approved?

No. There is currently no therapeutically equivalent version of Banzel available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Banzel. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Crystal modification of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and its use as antiepileptic
  Patent 6,740,669
  Issued: May 25, 2004
  Inventor(s): Robert; Portmann & Urs Christoph; Hofmeier & Andreas; Burkhard & Walter; Scherrer & Martin; Szelagiewicz
  Assignee(s): Novartis AG
  The invention relates to the novel modification A or A′ of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide of the formula its use and pharmaceutical preparations comprising this crystal modification.
  
  Patent expiration dates:
  
  
  • November 14, 2022
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • August 17, 2020
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Crystal modification A of 1-(2,6-difluorobenzyI)-1 H-1,2,3-triazole-4-carboxamide and dosage forms and formulations thereof
  Patent 8,076,362
  Issued: December 13, 2011
  Inventor(s): Portmann; Robert & Hofmeier; Urs Christoph & Burkhard; Andreas & Scherrer; Walter & Szelagiewicz; Martin
  Assignee(s): Novartis AG
  The invention relates to dosage forms and formulations comprising the novel crystal modification A of the compound I-(2,6-difluorobenzyl)-I H-I,2,3-triazole-4-carboxamide, wherein crystal modification A is characterized by characteristic lines with interplanar spacings (d values) of 10.5 Å, 5.14 Å, 4.84 Å, 4.55 Å, 4.34 Å, 4.07 Å, 3.51 Å, 3.48 Å, 3.25 Å, 3.19 Å, 3.15 Å, 3.07 Å, and 2.81 Å, determined by means of an X-ray powder pattern. Dosage forms of crystal modification A of the compound I-(2,6-difluorobenzyl)-I H-I,2,3-triazole-4-carboxamide may be for oral or parenteral administration, in the form of a solid or liquid, and in a dosage range of 20 mg to less than 500 mg. Solid dosage forms comprise a tablet or capsule, and further comprise a pharmaceutically-acceptable carrier and film-coat.
  
  Patent expiration dates:
  
  
  • June 8, 2018
    
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • November 14, 2013 - NEW CHEMICAL ENTITY
  
  
  • November 14, 2015 - ORPHAN DRUG EXCLUSIVITY
  
  

See also...

• Banzel Consumer Information (Drugs.com)
• Banzel Consumer Information (Wolters Kluwer)
• Banzel Consumer Information (Cerner Multum)
• Banzel Advanced Consumer Information (Micromedex)
• Banzel AHFS DI Monographs (ASHP)
• Rufinamide Consumer Information (Wolters Kluwer)
• Rufinamide Consumer Information (Cerner Multum)
• Rufinamide Advanced Consumer Information (Micromedex)
• Rufinamide AHFS DI Monographs (ASHP)